Fingolimod: 12 agencies, 2011–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 14.2 years separate the first record, 20 Jul 2011 at HAS (France), from the most recent, 26 Sep 2025 at CONITEC (Brazil).
SMC (Scotland) changed its position: restricted on 10 Sep 2012, recommended by 10 Jun 2019.
No assessment is on file from CIPM (Spain), which is among the eight highest-volume agencies here.
The file is active: 3 of 30 records date from 2023 or later.
6 distinct indication wordings are recorded for fingolimod by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 30 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess fingolimod, on 20 Jul 2011; NYE METODER (Norway) did not open a file until 20 Mar 2022 — an unusually long tail of 10.7 years between the earliest and latest system to look at it.
The record arrives in waves: 8 separate years each carry two or more decisions, spread across 12 years in total.
7 of the 12 agencies here assessed fingolimod more than once, HAS (France) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
fingolimod has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for fingolimod reads 19 recommended, 5 restricted, 3 not recommended and 1 no benefit, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CONITEC (Brazil) | 26 Sep 2025 | Tratamento de primeira linha de pacientes com esclerose múltipla remitente recorrente, de baixa e moderada atividade, em… | not incorporated | source |
| HAS (France) | 14 May 2025 | Re-assessment of SMR and ASMR | SMR substantial | source |
| PBAC (Australia) | 2024 | Multiple sclerosis (MS) | Recommended | source |
| NYE METODER (Norway) | 20 Mar 2022 | Behandling av relapserende remitterende multippel sklerose (RRMS) | introduced | source |
| AIFA (Italy) | 15 Sep 2020 | GILENYA e' indicato in monoterapia, come farmaco modificante la malattia, nella sclerosi multipla recidivante-remittente… | fully innovative, since expired | source |
25 further decisions for fingolimod, across 11 agencies, are not shown here. They link to 15 further source documents.
Related molecules
- teriflunomide — divergent outcome (recommended vs restricted) on a shared indication
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
Coverage: 30 decisions for fingolimod from 12 agencies, 2011 to 2025. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.